Wordt geladen...
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis
Significant advances in the management of patients with ulcerative colitis (UC) have been made since the introduction of anti-tumor necrosis factor (TNF)-alpha agents, especially for those who fail or do not tolerate conventional therapies. Two drugs, infliximab first, then adalimumab afterward, sho...
Bewaard in:
| Gepubliceerd in: | Drug Healthc Patient Saf |
|---|---|
| Hoofdauteurs: | , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Dove Medical Press
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4745853/ https://ncbi.nlm.nih.gov/pubmed/26893582 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DHPS.S62649 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|